COMMUNIQUÉS West-GlobeNewswire

Akers Biosciences Further Extends Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test

03/07/2018 - 13:00

THOROFARE, N.J., July 03, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces agreements with six [...]

Six zones de l’expansion de 250 000 pieds carrés des serres de HEXO sont maintenant entièrement autorisées et opérationnelles

03/07/2018 - 12:30

GATINEAU, Québec, 03 juill. 2018 (GLOBE NEWSWIRE) -- La Société Hydropothecary (TSX:HEXO) (« HEXO » ou « la Société ») est heureuse d'annoncer que six des dix zones de son expansion de 250 000 pieds carrés sont [...]

Six Zones of HEXO’s 250,000 sq. ft. Greenhouse Expansion Now Fully Licensed and Operational

03/07/2018 - 12:30

GATINEAU, Quebec, July 03, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (“HEXO” or the “Company”) (TSX:HEXO) is pleased to announce that six of ten zones in its 250,000 sq. ft. greenhouse expansion are now [...]

Virbac : Declaration of the number of shares and voting rights as of June 2018, 30.

03/07/2018 - 12:00

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]

Virbac : Déclaration d'actions et de droits de vote au 30 Juin 2018

03/07/2018 - 12:00

DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]

Transactions in relation to share buyback program

03/07/2018 - 10:12

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004

03/07/2018 - 10:01

SINGAPORE, July 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT) (NASDAQ:ASLN), a clinical-stage biopharmaceutical company based in Asia developing novel therapeutics for global markets, today [...]

FIT Biotech Oy: FIT Biotech webcasts the company half-year financial report on September 6th 2018, at 10.00 AM.

03/07/2018 - 09:01

FIT Biotech Oy Press Release July 3 rd 2018, 10.00 EET FIT Biotech webcasts the company half-year financial report on September 6 th 2018, at 10.00 AM. FIT Biotech's half-year financial report will be webcasted on [...]

Shire plc : Rule 2.9 Announcement

03/07/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 July 2018 Shire [...]

Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors

03/07/2018 - 08:00

NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Bertoldi has [...]

FIT Biotech Oy: FIT Biotech webcasts the company half-year financial report on September 6th 2018, at 10.00 AM.

03/07/2018 - 07:31

FIT Biotech Oy Press Release July 3 rd 2018, 08.30 EET FIT Biotech webcasts the company half-year financial report on September 6 th 2018, at 10.00 AM. FIT Biotech's half-year financial report will be webcasted on [...]

NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS

03/07/2018 - 07:01

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFN alpha KINOID IN THE TREATMENT OF LUPUS WHICH ALLOWS TO PROCEED WITH THE CLINICAL DEVELOPMENT INTO PHASE III THE [...]

NÉOVACS ANNONCE LES RÉSULTATS DE L'ÉTUDE DE PHASE IIB AVEC L'IFNalpha KINOÏDE POUR LE TRAITEMENT DU LUPUS

03/07/2018 - 07:01

COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS ANNONCE LES RÉSULTATS DE L'ÉTUDE DE PHASE IIB AVEC L'IFNalpha KINOÏDE POUR LE TRAITEMENT DU LUPUS AUTORISANT LA POURSUITE DU DÉVELOPPEMENT [...]

iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer

03/07/2018 - 07:00

iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer Gosselies, Belgium – July 3, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the [...]

Lexington Biosciences Announces Results of Annual General Meeting

03/07/2018 - 01:32

VANCOUVER, British Columbia, July 02, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, wishes to provide the [...]

Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal

02/07/2018 - 23:11

YARDLEY, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has [...]

Acasti Pharma Announces Annual Performance Grants of Stock Options, Amendment of Stock Option Plan and Issuance of Common Shares in Payment of Outstanding Interest under Debentures

02/07/2018 - 23:00

LAVAL, Québec, July 02, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ:ACST) (TSX-V:ACST), today announced the grant of stock options to its employees, executives and directors, and that [...]

Neuronetics, Inc., Maker of NeuroStar® Advanced Therapy, Announces Closing of Initial Public Offering and the Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

02/07/2018 - 22:48

MALVERN, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality of life for patients who [...]

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02/07/2018 - 22:32

EMERYVILLE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it [...]